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The role of miR-339 in human gastric cancer (GC) remains unclear. Here, we found that miR-339 is
remarkably decreased in primary GC tissues. Overexpression of miR-339 in GC cells significantly sup-
pressed proliferation, migration, invasion, and tumorigenicity. Furthermore, NOVA1 was confirmed
as a target of miR-339. Restoration of NOVA1 in miR-339-overexpressing GC cells partially impaired
the inhibitory effects of miR-339. More importantly, epigenetic modification may be involved in the
modulation of miR-339 expression. These findings uncover a novel role for miR-339 in gastric car-
cinogenesis, and restoration of miR-339 could be considered as a potential therapeutic strategy for
GC treatment.
 2015 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Gastric cancer (GC) is one of the leading causes of cancer related
death worldwide, with approximately 1 million new cases of GC
are diagnosed per year worldwide [1]. Although there have been
progress in treatment, the prognosis for GC remains unsatisfactory
[2]. Thus, it is of great significance to further exploration of the
molecular mechanisms underlying the initiation of GC to promote
the advancement of novel and efficient therapeutic targets for
treatment.
MicroRNAs (miRNAs) are a group of small, non-coding, single
stranded RNAs (approximately 22 nucleotides) that play critical
roles in post transcriptional regulation and functions as tumor pro-
moter or suppressor [3,4]. It has been confirmed that miRNAs reg-
ulate many tumor-related processes including proliferation,
migration, and invasion [5]. Accumulating studies has revealed
that dysregulation of miRNAs occurs in various human malignan-
cies, including GC [6,7]. Among these miRNAs, miR-339 wasreported to be deregulated in breast and colorectal cancer [8,9].
However, the function and potential mechanism of miR-339 in gas-
tric carcinogenesis is totally unknown.
In this study, the level of miR-339 in GC cells and tissues was
significantly decreased and overexpression of miR-339 suppressed
GC cell proliferation, cell cycle progression, invasion, and the
tumorigenicity of GC cells in xenograft models. Besides, we found
that NOVA1 was a direct target of miR-339. Overexpression of
NOVA1 impaired the inhibitory effects of miR-339 on GC cells.
For the first time, we suggested that epigenetic modulation may
be involved in the regulation of miR-339. Thus, our results revealed
that miR-339 is an tumor-suppressor and a potential therapeutic
target of GC.
2. Materials and methods
2.1. GC samples and cell lines
A total of 46 GC tissue specimens and adjacent non-malignant
tissues were surgically obtained from the Department of Oncology,
Jiangsu Cancer Hospital Affiliated to Nanjing Medical University,
between Jan 2011 and Feb 2012. Patients who were enrolled in this
study should fulfill the criteria as follows: (1) no radio- or
chemotherapy was given before surgery; (2) all tumors were ade-
nocarcinoma; (3) no prior cancer history. This study was approved
by the Ethics Committee of Jiangsu Cancer Hospital and informed
consent was obtained from all individuals. Both tumor samples
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senior pathologists independently. All tissue specimens were snap-
frozen in liquid nitrogen after resection.
Human GC cell line BGC-823, SGC-7901, MKN-28, AGS, and a
non-malignant gastric epithelium cell line GES-1 were obtained
from the American Type Culture Collection (ATCC, Manassas, VA,
USA), and cultured in RPMI-1640 medium (GIBCO, Carlsbad, CA).
2.2. Quantitative reverse-transcription PCR (qRT-PCR)
Total RNA was isolated using TRIzol reagent (Invitrogen, Carls-
bad, CA, USA). 10 ng total RNA and the TaqMan MicroRNA Assay
Kit (ABI, Foster City, CA, USA) were applied in qRT-PCR assay for
miR-339 detection. For NOVA1 mRNA measuring, PrimeScript RT
reagent Kit (Takara, Japan) was used in reverse transcription proce-
dure and the resulting cDNA was quantified with the ABI 7500
real-time PCR System (ABI) using SYBR Green Master Mix (Takara).
The 2DDCt method was used to quantify the relative levels of gene
expression. GAPDH and U6 was used as endogenous control for
normalizing NOVA1 and miR-339, respectively. All primers used
in this study are shown in Supplementary Table S1.
2.3. Oligonucleotide and plasmid transfection and lentivirus infection
miR-339 mimics, mimic negative control (NC-mim), miR-339
inhibitor and inhibitor negative control (NC-inh) were chemically
synthesized by GenePharma (Shanghai, China). Cells were trans-
fected using Lipofectamine 2000 (Invitrogen). To construct the
miR-339 expression vector, the sequence containing the miR-339
pre-miRNA was amplified by PCR and the final PCR product was
cloned into the XbaI/EcoRI sites of the pCDH-CMV-EF1-copGFP
vector (SBI, Germany).
The wild-type 30 UTR of NOVA1 containing the putative miR-
339 binding site was amplified and cloned into the pGL3-control
luciferase reporter vector (Promega, Madison, WI, USA). The
mutant constructs were generated using a QuickChange site-
directed mutagenesis kit (Stratagene, La Jolla, CA, USA). NOVA1
cDNA without its 30 UTR were inserted into pcDNA3.1 (Invitrogen)
to generate the recombinant vector.
2.4. Cell proliferation, colony formation and cell cycle analysis
SGC-7901 and BGC-823 cells (2  106) transfected with
miR-339 inhibitor or mimic were seeded in 96-well plates and
then stained with 100 lL MTT. The culture medium was removed
and 150 lL DMSO (Sigma, St. Louis, Mo, USA) was added. Absor-
bance was measured at 490 nm.
For the colony formation assay, GC cells were seeded onto a
6-well plate after transfection. After 10 days, the colonies were
stained with 1% crystal violet for 5 min after fixation with metha-
nol for 10 min, and visible colonies were counted. For the cell cycle
analysis, GC cells were harvested by trypsinization, washed twice
and fixed. Finally, cell cycle assay was performed with FACS flow
cytometry (BD Biosciences, Franklin Lakes, NJ).
2.5. Migration and invasion assays
A wound-healing assay was conducted to assess cell migratory
capability. An artificial wound was created on a confluent cell
monolayer without FBS using a 200 lL pipette tip 24 h after
transfection. Images were taken at 0, and 48 h. The invasive ability
of GC cells transfected with miR-339 mimic or inhibitor
(1  105 cells/well) was assessed in Matrigel coated cell culture
chambers. Medium with 10% FBS was added into the lower cham-
bers. After 24 h of incubation, the cells that had invaded through
the membrane were fixed and stained.2.6. DNA extraction, methylation-specific PCR (MSP) and bisulfite
sequencing PCR (BSP)
Genomic DNA was extracted using a QIAamp DNA Mini Kit
(Qiagen, Hilden, Germany) and then modified by using EpiTect
Bisulfite Kit (Qiagen). Genomic DNA from cell lines and 5 pairs of
GC and adjacent normal tissue was used in MSP assay. DNA from
cells was PCR-amplified using either the methylated or the
unmethylated primer pairs, while DNA from tissue samples using
methylated primer only. The DNA from peripheral blood lympho-
cyte was treated with SssI methyltransferase (New England, Bev-
erly, MA) and was used as a positive control for methylated alleles.
Genomic DNA from GES-1, SGC-7901 and BGC-823 cells and 1
non-malignant tissue specimen were used in BSP analysis. The
PCR products were extracted and then cloned into the pCR2.1-
TOPO vector (Sangon, China). After bacterial amplification of the
cloned PCR fragments by standard proceedings, 5 clones were
selected to DNA sequencing.
2.7. 5-Aza-20-deoxygcitidine (5-Aza) treatment
GC (2  105) cells were seeded and treated with 5-Aza (2.5 lM
and 5 lM, Sigma). Cells were cultured for 3 days with a change of
fresh medium every 24 h.
2.8. Xenograft model in nude mice
All animal experiments were conducted according to the
guidelines of the Nanjing Medical University Institutional Animal
Care and Use Committee. Five nude mice (BALB/c nude mice,
Vitalriver, China; 4-weeks old) were injected into one flank
with SGC-7901 (2  106 cells) cells transfected with miR-339
over-expressing vectors and the other flank with empty vectors,
so that tumor comparisons were controlled for each mouse.
4 weeks later, mice were euthanized and the tumors were
weighed.
2.9. Western blot
Cell extracts were cleared by centrifugation at 12,000g for
10 min at 4 C, and the supernatant was used for Western blot
analyses. After blocking in 5% fat-free milk for 1 h, the membranes
were washed four times with a mixture of Tris-buffered saline
(TBS) and 0.05% Tween-20 (TBST) at room temperature and then
incubated overnight at 4 C with the following primary antibodies:
NOVA1 (1:1000; Santa Cruz Biotechnology, Santa Cruz, CA, USA),
MMP2 (1:1000, Cell Signaling, Boston, MA), MMP9 (1:1000, Cell
Signaling), CyclinD1 (1:1000, Cell Signaling), and GADPH
(1:1500; Santa Cruz). Then, membranes were incubated with sec-
ondary antibody (horseradish peroxidase-conjugated goat anti-
mouse IgG, 1:2000; Santa Cruz) for 1 h.
2.10. Putative targets prediction
Three bioinformatics algorithms including TargetScan,
MicroRNA and miRDB were used to searching for putative targets
of miR-339. We were interested in NOVA1, which was a common
target predicted by using above three database and promoted pro-
liferation and invasion in astrocytoma, as well as frequently unreg-
ulated in tumors [10,11].
2.11. Statistical analysis
Data were presented as means ± SD. Differences between two
groups were analyzed by Student’s t test. Pearson Correlation anal-
ysis was used to analyze correlation between levels of miR-339
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cally significant when P < 0.05.
3. Results
3.1. Low expression of miR-339 and overexpression of NOVA1 in GC
Compared with the non-malignant tissues, miR-339 expression
was significantly downregulated in tumor tissues (0.0224 ± 0.0133
vs. 0.0175 ± 0.0086, P = 0.0018, Fig. 1A). In contrast, the mRNA level
of NOVA1 was significantly elevated in GC samples compared with
non-tumor tissues (3.6904 ± 1.7182 vs. 4.4668 ± 1.7738, P = 0.0002,
Fig. 1B). The Pearson Correlation analysis clearly showed a negative
correlation between miR-339 and NOVA1mRNA level in GC tissues
(Pearson r = 0.3828, P = 0.0086, Fig. 1C). Besides, reduced miR-
339 was significantly associated with the higher TNM stage
(P = 0.011), larger tumor size (P = 0.005) and lymph node metasta-
sis (P = 0.035, Table 1). The mRNA expression of NOVA1 showed no
significant correlation with clinicopathological features (Table 1).
The completely follow-up data were also analyzed and cases wereFig. 1. NOVA1 was a direct target of miR-339. (A) Expression level of miR-339 in samples
tissue specimens. (C) Analysis of correlation betweenmiR-339 and NOVA1 expression in t
(E) Expression level of miR-339 in GC cells and GES-1. (F) miR-339 and its putative
complementary site that binds to the seed region of miR-339. (G) miR-339 mimic was co
mutant-type (Mut) NOVA1 30 UTR into cells. The relative luciferase activity was measured
339 mimic and NOVA1 mRNA (H) and protein (I) levels were analyzed. ***P < 0.001. **P <divided into two groups according to the median of miR-339 and
NOVA1mRNA levels: high or low expression. Both low levels of
miR-339 and high levels of NOVA1 were notably correlated with
a poorer prognosis (P = 0.044 and 0.022, respectively, Fig. 1D and
Supplementary Fig. S1).
Besides, decreased miR-339 expression was observed in four GC
cells compared to GES-1 cells (P < 0.001, Fig. 1E). BGC-823 and
SGC-7901 cells were selected for further analysis owing to their
relatively low expression level of miR-339.
3.2. NOVA1 is a direct target of miR-339
As shown in Fig. 1F, the 30 UTR of human NOVA1 contains
putative target sites for miR-339. Enhanced expression of
miR-339 in SGC-7901 and BGC-823 cells remarkably reduced
the luciferase activity of the reporter gene with the wild-type
construct but not with the mutant construct (Fig. 1G).
Besides, protein and mRNA levels of NOVA1 were also
dramatically suppressed in miR-339 over-expressing cells
(Fig. 1H and I).of GC tissue and adjacent normal tissue (Adj-NT). (B) The mRNA levels of NOVA1 in
umors. (D) Kaplan–Meier curves for overall survival analysis by miR-339 expression.
binding sequences in the 30 UTR of NOVA1. Mutations were generated in the
-transfected with luciferase plasmids containing wide-type (WT) NOVA1 30 UTR or
. (H and I) GC cells were transfected with mimic negative control (NC-mim) or miR-
0.01.
Table 1
Correlation between clinicopathological features and the expression of miR-339 and NOVA1 mRNA in patients with GC.
Characteristics No. of patients miR-339 level p Value NOVA1 mRNA p Value
n = 46 (mean ± SD) (mean ± SD)
Gender 0.543a 0.252a
Female 14 0.0166 ± 0.0097 4.0584 ± 1.9195
Male 32 0.0179 ± 0.0082 4.6455 ± 1.7071
Age (years) 0.675a 0.620a
<50 25 0.0165 ± 0.0075 4.5829 ± 1.6021
P50 21 0.0188 ± 0.0097 4.3827 ± 1.9907
Differentiation 0.712b 0.219b
Well 6 0.0162 ± 0.0066 3.4780 ± 1.0436
Moderate 24 0.0183 ± 0.0094 4.9198 ± 2.0138
Poor 16 0.0168 ± 0.0082 4.1582 ± 1.4276
TNM stage 0.011a 0.956a
I, II 19 0.0204 ± 0.0069 4.7911 ± 1.9073
III, IV 27 0.0155 ± 0.0092 4.4582 ± 1.7110
Tumor size (cm) 0.005b 0.447b
T < 2 17 0.0213 ± 0.0078 4.0980 ± 1.5234
2 6 T < 5 15 0.0179 ± 0.0099 4.3107 ± 1.9893
TP 5 11 0.0113 ± 0.0049 5.0425 ± 1.8163
Missing 3 0.0172 ± 0.0044 5.2267 ± 2.0031
Nerves 0.982a 0.801a
Negative 43 0.0176 ± 0.0088 4.4557 ± 1.7864
Positive 3 0.0162 ± 0.0046 4.6260 ± 1.9354
Vessels 0.543a 0.867a
Negative 32 0.0182 ± 0.0095 4.485 ± 1.8468
Positive 14 0.0152 ± 0.0057 4.425 ± 1.6602
Lymph node 0.035a 0.236a
Negative 17 0.0203 ± 0.0089 4.2233 ± 1.7769
Positive 29 0.0159 ± 0.0081 4.8351 ± 1.6524
Tumor site 0.359b 0.826b
Antrum 31 0.0188 ± 0.0088 4.4691 ± 1.8081
Cardia 9 0.0154 ± 0.0057 4.7436 ± 1.9289
Body 6 0.0143 ± 0.0106 4.0395 ± 1.5470
a Calculated by Mann–Whitney test.
b Calculated by Kruskal–Wallis test; GC, gastric cancer; P < 0.05 are present in bold.
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To reveal the role of miR-339 in GC progression, gain- and loss-
of-function analysis were performed. The results showed that miR-
339 mimic transfection raised miR-339 expression (Fig. 2A) as well
as reduced cell proliferation and colony formation, while miR-339
inhibitor displayed the opposite effects on GC cells (Fig. 2B and C).
To understand the mechanism of how miR-339 regulated GC cell
proliferation, we explored whether miR-339 has an effect on cell
cycle progression. The data indicated that upregulation of miR-
339 induced G1 phase arrest, while inhibition of miR-339 led to
a significant reduce in the cellular population in G0/G1 phase but
a sharp increase in S phase (Fig. 2D).
Moreover, the capability of migratory and invasive of GC cells
were inhibited by miR-339 mimic, while promoted by miR-339
inhibitor (Fig. 2E and F). We also detected expression of the migra-
tion and cell cycle-related proteins and found that MMP2, MMP9
and CyclinD1 were noticeably decreased in miR-339 mimic trans-
fection cells, while increased in miR-339 inhibitor transfection
cells (Fig. 2G). These results suggested that the downregulation
of miR-339 promotes tumor growth and metastasis in gastric
carcinogenesis.
3.4. NOVA1 is involved in miR-339-induced effects on GC proliferation
and invasion
To verify whether the tumor suppressive effects of miR-339 are
regulated by NOVA1, BGC-823/SGC-7901-miR-339 cells were
transfected with NOVA1 expression plasmids lacking 30 UTR to res-
cue NOVA1 expression (Fig. 3A). As shown in Fig. 3B–D, NOVA1
overexpression significantly impaired the inhibitory effect of
miR-339 on GC cells. Taken together, these observations suggested
that NOVA1 is involved in miR-339-induced effects on GC cells.3.5. miR-339 promotes tumorigenesis of GC cells in vivo
For the more evidence of the tumor suppressor role of miR-339,
we performed xenografts assay. Compared with the control vector,
miR-339 overexpression significantly decreased xenografts growth
(Fig. 4A) and tumor weight (Fig. 4B). The significantly increased
level of miR-339 in xenograft tumors over-expressing miR-339
was confirmed by qRT-PCR (Fig. 4C). NOVA1 protein was reduced
in xenografts over-expressing miR-339 cells compared with con-
trol xenografts (Fig. 4D). These findings were consistent with the
in vitro findings and indicated that miR-339 has the ability to sup-
press GC cell growth in vivo.
3.6. miR-339 is hypermethylated in GC
Using ‘‘CpG Island Searcher’’ software, we found a CpG islands
around miR-339 (Supplementary Fig. S2). MSP analysis showed
that the CpG island around miR-339 was hypermethylated in GC
cell lines and hypomethylated in GES-1 cells (Fig. 5A), which was
consistent with the low expression of miR-339 in these GC cells.
In addition, the intensity of methylation alleles in tumors was
obviously stronger than that in non-malignant tissues (Fig. 5A).
We next conducted BSP to confirm the methylation status
of the individual CpG sites within the CpG island (155 to
+187 bp, containing 27 CpG sites). The results illustrated that the
methylation levels were significantly higher in GC cell lines,
compared with GES-1 and a sample of adjacent normal tissue
(Fig. 5B). While 77.1% and 71.9% of CpGs were methylated in
SGC-7901 and BGC-823 cells, respectively, only 44.2% and 24.6%
of CpGs were methylated in GES-1 cells and normal samples,
respectively.
Besides, we found that the treatment of cells with 5-Aza signif-
icantly elevated the expression of miR-339 in both cells (Fig. 5C),
Fig. 2. miR-339 inhibited GC cell proliferation and motility. (A) miR-339 expression in SGC-7901 and BGC-823 cells after miR-339 inhibitor or mimic transfection. (B) MTT
assay for testing cell proliferation rate. (C) Colony formation assay. (D) Determination of cell cycle with flow cytometry. (E) The wound healing assays showed the migratory
capability of cells. (F) Transwell invasion assay showed that miR-339 significantly suppressed cell invasion. (G) The protein levels of MMP2, MMP9, and CyclinD1 after up- or
downregulation of miR-339. *P < 0.05; **P < 0.01.
Fig. 3. Overexpression of NOVA1 attenuates the tumor suppressive role of miR-339. (A) Western blot analysis of NOVA1. (B) MTT assays for cell proliferation. (C) The wound
healing assay was used to assay migration of GC cells. (D) The invasion assay showed invasion capability of GC cells. *P < 0.05; **P < 0.01.
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Fig. 4. miR-339 inhibited tumorigenicity in a xenograft model. (A) SGC-7901 cells which were stably transfected with miR-339 or empty vector were subcutaneously injected
into nude mice (n = 5). After 28 days, tumors were harvested and representative tumors were shown. (B) Tumors were weighted. (C) The expression of miR-339 was detected
in xenografts. (D) NOVA1 protein were measured using Western blot in xenografts. **P < 0.01.
Fig. 5. Hypermethylation of miR-339 in GC. (A) Up: MSP analysis of miR-339 in
SGC-7901, BGC-823, and GES-1 cells. M, methylated allele; U, unmethylated allele.
down: MSP was also performed using tumors and matched non-tumor tissues. (B)
BSP results of miR-339 in GC cells, GES-1 and one sample of adjacent normal tissue
(Adj-NT). The open and filled circles represent the unmethylated and methylated
CpGs, respectively. (C) Demethylation treatment with 5-Aza could restore miR-339
expression in GC cells. *P < 0.05; **P < 0.01.
3210 B. Shen et al. / FEBS Letters 589 (2015) 3205–3211indicating that the epigenetic regulation might be a potential
mechanism for miR-339 downregulation.
4. Discussion
The biological role of majority miRNAs in the initiation and pro-
gression of GC remain unclear. Therefore, investigation the func-
tions and underlying mechanisms of miRNAs in GC may help us
to understand the pathogenesis of GC and provide novel therapeu-
tic targets. In the present study, we focus on the role of miR-339
(hsa-miR-339-5p) in GC progression.
Firstly, the expression level of miR-339 is significantly lower in
GC cells and tissues than in GES-1 and non-malignant tissues,
which was consistent with former studies [8,9,12]. Downregulated
miR-339 correlates with poorer prognosis, which was in accor-
dance with previous studies [13], implying the potential of miR-
339 as a promising marker for cancer prognosis. Besides, decreased
miR-339 was significantly associated with lymph node metastasis,
suggesting its suppressive effect on tumor cell motility. Bioinfor-
matic prediction and experimental analyses demonstrated that
NOVA1 was a direct and functional target of miR-339. Upregulated
NOVA1 was observed in our data and former reports [10,11], indi-
cating the prognostic value of NOVA1 in cancer. Certainly, the cor-
relation between NOVA1 and clinicopathological characteristics
needs further studies from a large cohort of cancer cases. Our data
provide the novel insight that enhanced NOVA1 might be involved
in GC progression.
Functionally, loss- and gain-of-function analysis indicated that
miR-339 inhibits proliferation, migration, invasion of GC cells
and suppresses tumorigenesis in vivo, indicating the tumor sup-
pressor role of miR-339 in GC. Similarly, miR-339-5p markedly
decreased the ability of migration and invasion of lung cancer cells
[14]. Moreover, overexpression of NOVA1attenuates the suppres-
sive role of miR-339, suggested that miR-339 modulates tumor
growth through targeting NOVA1 in GC. These observations pro-
vide the first clue, that miR-339 mechanistically acts via the regu-
lation of NOVA1. miR-339-5p was reported as a regulator of p53
pathway and p-ERK1/2 by targeting MDM2 and PRL-1, respectively
[15,8]. All of these results including us implied that miR-339 was
involved in tumorigenesis by regulating multiple targets in tumors
and may be applied as a therapeutic target.
miRNAs have been reported to dysregulated in many cancers.
However, only a few studies have been revealed the underlying
mechanism responsible for the alteration of miRNAs in cancer
development. Epigenetic modifications have been shown to be
key reason for downregulating miRNAs in carcinogenesis [16,17].
Our data demonstrated that the hypermethylation of the CpG
island around miR-339 associates with the downregulation of
miR-339 in GC cells. Similarly, DNA methylation-regulated down-
regulation of miRNAs by proximal CpG islands has been reported
by a number of groups [18–20]. These data indicated that epige-
netic regulation maybe a reason for the silencing of miR-339.
B. Shen et al. / FEBS Letters 589 (2015) 3205–3211 3211In conclusion, this study reports that miR-339 acts as a tumor
suppressor in GC by targeting NOVA1 and is partly downregulated
by DNA hypermethylation. Our findings suggested that miR-339
might play an important role in gastric carcinogenesis, and the
restoration of miR-339 may provide a novel therapeutic strategy
for GC treatment.
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